-
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
-
EMA Takes Action on Metamizole-Induced Risks
EMA
The EMA has issued new recommendations to mitigate agranulocytosis risks associated with metamizole, urging increased awareness among healthcare providers and patients. Symptoms include fever and sore throat; immediate medical attention is crucial.
-
-
-
EMA's CHMP June 2024 Approvals and Recommendations
EMA
In June 2024, the EMA's CHMP recommended 10 new medicines for approval, including Balversa for urothelial carcinoma and Eurneffy, the first nasal spray for allergic reactions. Notable approvals also include mResvia, an mRNA vaccine for RSV, and treatments for various cancers and rare diseases.
-
-
漠河县|
贵定县|
惠水县|
信阳市|
常山县|
云林县|
永兴县|
雷波县|
永春县|
呈贡县|
友谊县|
德江县|
家居|
逊克县|
北碚区|
沙河市|
卫辉市|
石屏县|
井陉县|
龙泉市|
西峡县|
彭州市|
岐山县|
手游|
宁化县|
信宜市|
黑水县|
商南县|
讷河市|
嘉兴市|
新郑市|
汉川市|
苍溪县|
垫江县|
北海市|
金川县|
阳朔县|
海南省|
仁化县|
枣阳市|
永定县|